Stoke Therapeutics (STOK) insider sale tied to tax withholding
Rhea-AI Filing Summary
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by officer Jonathan Allan (General Counsel & Corporate Secretary). On August 14, 2026, Allan exercised 6,000 Performance Stock Units into 6,000 shares of common stock at a stated price of $0.00 per share, reducing that PSU award balance to zero. The award’s achievement had been certified on August 14, 2025, with half vesting then and the remainder vesting on August 14, 2026, subject to continued service. On August 18, 2026, the broker sold a total of 2,861 common shares in open-market transactions at weighted average prices of $32.01$32.47 per share, in an issuer-mandated sale to satisfy tax withholding liabilities related to restricted stock unit vesting and settlement.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Allan Jonathan
Role
GENERAL COUNSEL & CORP SEC
Sold
2,861 shs ($92K)
Approx. gross sale proceeds
$92K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 2,716 | $32.0072 | $87K |
| Sale | Common Stock F1, F3 | 145 | $32.4681 | $5K |
| Exercise | Performance Stock Units F4, F5 | 6,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,000 | $0.00 | $0.00 |
Holdings After Transaction:
Performance Stock Units — 0 shares (Direct);
Common Stock — 21,225 shares (Direct)
Footnotes (5)
- F1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
- F4. Each performance stock unit represents a right to receive one share of the Issuer's common stock.
- F5. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Key Figures
Common shares sold: 2,716 shares
Additional common shares sold: 145 shares
Weighted average sale price (main block): $32.0072 per share
+5 more
8 metrics
Common shares sold
2,716 shares
Open-market sale on August 18, 2026 at weighted average price qualified by range $31.40–$32.36
Additional common shares sold
145 shares
Open-market sale on August 18, 2026 at weighted average price qualified by range $32.44–$32.54
Weighted average sale price (main block)
$32.0072 per share
Sale of 2,716 shares on August 18, 2026; prices ranged from $31.40 to $32.36
Weighted average sale price (smaller block)
$32.4681 per share
Sale of 145 shares on August 18, 2026; prices ranged from $32.44 to $32.54
Performance Stock Units exercised
6,000 units
PSUs converted into 6,000 shares of common stock on August 14, 2026
PSU exercise price
$0.00 per unit
Each Performance Stock Unit represented a right to receive one share of common stock
PSUs remaining from award
0 units
Total shares following derivative transaction for the reported PSU award
Net buy/sell shares (common stock)
-2,861 shares
Net of reported buy/sell activity in common stock transactions during the period
Key Terms
Performance Stock Units, restricted stock units, weighted average price, tax withholding liabilities
4 terms
Performance Stock Units financial
"Each performance stock unit represents a right to receive one share"
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
restricted stock units financial
"sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding liabilities financial
"sale to satisfy tax withholding liabilities in connection with the vesting"
FAQ
What insider transactions did STOK’s Jonathan Allan report on this Form 4?
Jonathan Allan reported exercising 6,000 Performance Stock Units into common stock on August 14, 2026, and selling 2,861 shares of Stoke Therapeutics common stock on August 18, 2026, primarily to satisfy tax withholding liabilities related to restricted stock unit vesting.
What happened to Jonathan Allan’s Performance Stock Units in Stoke Therapeutics (STOK)?
Allan exercised 6,000 Performance Stock Units into 6,000 shares of STOK common stock on August 14, 2026, at a stated price of $0.00 per unit, leaving 0 PSUs from that particular award outstanding after the transaction, per the filing data.
How was the vesting of Jonathan Allan’s STOK performance award structured?
The company certified achievement of the performance stock unit award on August 14, 2025. Under the award agreement, half vested on August 14, 2025, and the remaining half vests on August 14, 2026, conditional on Allan’s continued service with Stoke Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
